Open AccessHow real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity
Author(s) -
D. Karateev
Publication year - 2014
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2014-2-35-40
Subject(s) - immunogenicity , etanercept , golimumab , certolizumab pegol , discontinuation , medicine , tumor necrosis factor alpha , rheumatoid arthritis , pharmacology , monoclonal antibody , infliximab , fusion protein , abatacept , epitope , immunology , antibody , recombinant dna , chemistry , biochemistry , rituximab , gene